I'm not sure what that analyst has been smoking, but he seems to have lost his mind. "narrower marketability"? No explanation provided on why that is the case.
"higher competition" - lol, please let us know who the emerging competitors are because all I've read about are other major pharmaceuticals like Pfizer and Eli Lilley abandoning their drug tanezumab because of significant risks of adverse events for a very marginal benefit. Big pharma have thrown billions at this and not cracked the puzzle.
Meanwhile, we have hundreds of people going through the SAS program, going from unbearable pain just walking to their post box, to being able to even manage to run a few kilometres a day..
research reports and media, page-2169
-
- There are more pages in this discussion • 2,187 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 25.0¢ | 23.0¢ | $211.2K | 895.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 82174 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 49300 | 8 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |